Stock Analysis
Medline Inc. Class A common stockMDLN
P/E 27.22×· 1Y range 23.62–34.35×· 44th percentile of history
Sector: Healthcare · Industry: Surgical & Medical Instruments & Apparatus
AnalystsStrong Buy34 analystsP/E 27.2× sits at the 44th percentile of its 0.8294547113848962-year history.
Cash covers 15% of debt · FY 2025.
PMP Verdict
Weak fundamentals
Strengths
- Financial Health65
Risks
- Growth24
- Profitability28
Weak fundamentals — valuation is the only support.
Bull Case
- ✓Piotroski F-Score 7/9 — high earnings quality
What's happening with MDLN
Profile
moat, growth and profitability lag behind.
How is each axis scored?
- Valuation69/100 · Moderate
- P/E vs own history (44th pct)12/25
- FCF yield (5.0%)20/25
- P/S (1.1x)25/25
- EV/EBIT (22.8x)12/25
- Growth24/100 · Weak
- Revenue CAGR (9.9%)12/25
- Net income CAGR (n/a)0/25
- EPS CAGR 5Y (n/a)0/25
- Fwd implied growth (12.8%)12/25
- Profitability28/100 · Weak
- ROIC (6.8%)5/25
- ROE (10.8%)12/25
- Net margin (3.9%)6/25
- Operating margin (6.2%)5/25
- Financial Health65/100 · Moderate
- Altman Z (2.09)18/25
- Current ratio (4.29)25/25
- Interest coverage (2.4x)10/25
- Net cash / debt (D/A 28%)12/25
- Quality59/100 · Moderate
- Piotroski F (7/9)22/25
- Beneish M (-2.20)12/25
- FCF conversion (n/a)0/25
- Margin stability (σ 1.6%)25/25
- Moat21/100 · Weak
- ROIC >12% years (0/3 yrs)0/25
- Median gross margin (25.9%)6/25
- FCF-positive years (3/4 yrs)10/25
- Worst-year net margin (worst -0.1%)5/25
Risk Flags
- ⚠Interest coverage 2.4× — thin debt cushion
About Medline Inc. Class A common stock
Medline is the largest provider of medical-surgical products and supply chain solutions in the US. Show more
The company generates over 90% of its revenue domestically and serves some of the largest US health systems. Medline offers approximately 190,000 Medline-branded products across more than 250 product families—including front-line care, surgical solutions, and laboratory and diagnostics—as well as roughly 150,000 third-party products sourced from over 1,250 vendors. The company maintains prime vendor relationships with many customers, acting as the primary consolidated logistics partner for their medical-surgical needs. Medline has significant scale, supported by more than 30 manufacturing facilities and a fleet of over 2,000 owned delivery trucks. Medline went public in December 2025.
Headquarters: NORTHFIELD, IL · Employees: 45,000 · Website ↗
Price History
Weekly Candlestick Chart — up to 5Y
Key Metrics
Financial snapshot · Tap any metric for its definition and grade
TTM Snapshot
trailing twelve months · YoYValuation
69BP/E (TTM)27.2xC
Grade C: ExpensivePrice / TTM EPS (own statements) — vs own hist. history: 23.6x–34.3x · 44th pct
P/FCF31.1xC
Grade C: ExpensivePrice / Free Cash Flow per share (Finnhub). Inverse of FCF yield — negative when FCF is negative
FCF Yield5.0%A
Grade A: ValueTTM (OCF − CapEx) / Market Cap — vs own hist. history: 2.5%–5.7% · 78th pct
P/S (TTM)1.05xA
Grade A: CheapPrice / TTM Revenue (own statements) — vs own hist. history: 0.9x–1.5x · 33rd pct
EV/EBIT22.8xC
Grade C: ExpensiveEnterprise value / TTM EBIT (D&A not in our data) — capital-structure neutral — vs own hist. history: 18.3x–26.3x · 76th pct
EV/Sales—
Enterprise Value / TTM Revenue (Finnhub) — capital-structure neutral sales multiple
Forward P/E24.1xB
Grade B: FairPrice / next-year EPS estimate — shows whether the TTM multiple is rich or just front-loading growth
P/B Ratio2.94xA
Grade A: FairPrice to Book Value. Neg. equity = heavy buybacks
PEG Ratio—
Finnhub PEG — their P/E basis ÷ expected EPS growth. Suppressed when their P/E diverges >2× from our TTM P/E (different basis)
Dividend Yield—
TTM dividend yield (Finnhub) — annual dividends / price. None = no dividend; very high yield can signal distress
Payout Ratio—
Dividends / Net Income (Finnhub) — share of earnings paid out; >90% or negative = unsustainable
Profitability
28EROIC6.8%D
Grade D: LowNOPAT (EBIT less ~21% tax) / invested capital (equity + debt − cash). Flagship quality metric — durable >15% signals a moat
ROE10.8%C
Grade C: AverageReturn on Equity. Neg. equity = heavy buybacks
ROA1.8%D
Grade D: WeakReturn on Assets (Finnhub) — Net Income / Total Assets; how efficiently assets produce profit
Net Margin3.9%D
Grade D: LowNet Income / Revenue
Operating Margin6.2%D
Grade D: LowTTM EBIT / TTM Revenue
Gross Margin26.2%D
Grade D: LowGross Profit / Revenue
FCF Margin5.3%D
Grade D: LowFCF / Revenue
True FCF Margin5.0%D
Grade D: LowTTM (OCF − CapEx − SBC) / TTM Revenue — SBC treated as a real cost
Growth
24ERevenue CAGR9.9%C
Grade C: OkCompound annual revenue growth (up to 5Y depending on data availability)
Net Income CAGR—
Compound annual net income growth (up to 5Y depending on data availability)
EPS CAGR (5Y)—
Compound annual EPS growth over up to 5Y of per-share earnings (own statements). Null when either endpoint EPS ≤ 0
Implied EPS Growth12.8%B
Grade B: LowAnalyst forward EPS (normalized basis) vs our GAAP TTM EPS — different bases, so extreme values usually mark cyclically depressed TTM earnings, not real growth
Dilution (5Y)—
Share count change over 5Y
SBC / Net Income8.1%A
Grade A: LowStock-based comp/Net income. >30% = dilution risk
SBC / Revenue0.3%A
Grade A: LowTTM stock-based comp / TTM Revenue
Financial Health
65BAltman Z-Score2.09C
Grade C: Gray zoneBankruptcy risk. >3 Safe, <1.8 Distress
Current Ratio4.29xA
Grade A: HighCurrent Assets/Liabilities
Quick Ratio2.61xA
Grade A: High(Current Assets − Inventory) / Current Liabilities (Finnhub) — stricter liquidity test, excludes inventory
Interest Coverage2.4xD
Grade D: RiskyEBIT/Interest. >10 Strong
Debt Repayment6.7yC
Grade C: AverageYears to repay net debt via FCF
Net Debt/EBIT5.7xD
Grade D: HighLeverage. <2x Low, >4x High
Debt/Equity1.17xC
Grade C: MedDebt / Equity: <1 Conservative, >2 Risky. Not meaningful with non-positive equity; shown as unavailable rather than low debt.
Cash / Debt0.15xD
Grade D: ThinCash covers how much of total debt. >1 = could repay all debt from cash
Quality
59CPiotroski F-Score7/9A
Grade A: StrongFinancial strength 0–9. >7 Strong
Beneish M-Score-2.20C
Grade C: Gray zoneEarnings manipulation risk. < -2.22 Safe
FCF Conversion—
FCF / Net Income
Margin Stability1.6%A
Grade A: StableEBIT margin std deviation. Lower = stable
Capex / Revenue1.4%A
Grade A: Asset-lightTTM CapEx / TTM Revenue — high % = capital-hungry business
Asset Turnover0.78xC
Grade C: AverageRevenue / Total Assets (Finnhub) — how efficiently the asset base generates sales
Insider Transactions
SEC Form 4 · 8 recordsP/S codes are the directional signal; grants, option exercises and tax withholding carry none. Form 4 doesn't flag 10b5-1 plans — scheduled sales may appear within open-market sells.
| Trade date | Insider | Transaction | Shares | Filed |
|---|---|---|---|---|
GIC Private Ltd Filed | GIC Private Ltd | SellOpen market sale | -7816987 | |
GIC Private Ltd Filed | GIC Private Ltd | SellOpen market sale | -7183013 | |
GIC Private Ltd Filed | GIC Private Ltd | SellOpen market sale | -2088987 | |
GIC Private Ltd Filed | GIC Private Ltd | SellOpen market sale | -1688690 | |
GIC Private Ltd Filed | GIC Private Ltd | SellOpen market sale | -7146941 |
Show 3 more filingsShow fewer filings
| Trade date | Insider | Transaction | Shares | Filed |
|---|---|---|---|---|
GIC Private Ltd Filed | GIC Private Ltd | SellOpen market sale | -2570999 | |
Miller Stephen L Filed | Miller Stephen L | Grant / award | +87.7K | |
Boyle James M Filed | Boyle James M | Grant / award | +764.3K |
More metrics — Moat, Per Share, Balance Sheet, MarketHide additional metrics
Moat
21EROIC >12% Years0/3 yrsD
Grade D: WeakShare of completed fiscal years with ROIC > 12% — measures multi-year capital-return durability
Gross Margin (Med.)25.9%D
Grade D: WeakMedian annual gross margin across available fiscal years — pricing-power durability
FCF-Positive Years3/4 yrsD
Grade D: WeakShare of completed fiscal years with positive free cash flow
Net Margin Floor-0.1%D
Grade D: WeakWeakest annual net margin across completed fiscal years — recession/downcycle resilience
Per Share
EPS (TTM)$1.32
Own TTM net income / shares — same earnings basis as P/E
Cash / Share$2.04
Cash & short-term investments per share (Finnhub)
Book Value / Share$8.81
Shareholders' equity per share (Finnhub). Negative = accumulated losses / heavy buybacks
Balance Sheet
Total Debt$12.56B
Total debt obligations (short + long term)
Cash & Equiv.$1.94B
Cash and short-term investments
Net Debt$10.62B
Total Debt minus Cash. Negative = Net Cash position
Total Equity$10.74B
Shareholders' equity (book value)
Asset / Liability2.00xA
Grade A: SolidTotal Assets / Total Liabilities
Market
Market Cap$31.55B
Current Market Capitalization
Beta0.95B
Grade B: MarketPrice sensitivity vs the market (Finnhub) — 1.0 moves with market, >1.2 amplifies swings
How grades work: each metric is graded A–D against fixed thresholds (tap a row for the meaning). Card grades map the pillar score to A+–E — a card grade is that pillar's own score, not an average of the rows shown.
Financials as of Jun 2026 · Ratio snapshot Oct 17, 2026
Key Insights: Medline Inc. Class A common stock (MDLN)
MDLN is down 1.67% at the last close. Medline Inc. Class A common stock meets 7 of 9 Piotroski F-Score criteria, placing its fundamental strength in the top tier of US-listed stocks. Altman Z-Score of 2.09 falls in the grey zone (1.81–2.99) — financial distress is unlikely but not ruled out.
- Takes ~6.7 years to repay net debt from free cash flow.
- Medline Inc. Class A common stock posted a net loss in 1 of 4 available completed fiscal years (2022–2025).
See how MDLN ranks on the Capex Tracker — top 50 capital spenders compared.
Recent Market Moves
See all MDLN moves →| Date | Session | Price | Move | Z-Score |
|---|---|---|---|---|
| Sep 22 | Regular | 34.47 | +7.84% | 3.41 |
| Sep 22 | After-hours | 33.60 | +5.13% | 2.32 |
Frequently Asked Questions about MDLN
What is the current Medline Inc. Class A common stock (MDLN) stock price?
MDLN is trading at $35.96 at the last market close, down 1.67% on the session. PreMarketPrice tracks MDLN pre-market, intraday and after-hours prices.
Is MDLN stock a buy right now?
PreMarketPrice's quantitative model rates Medline Inc. Class A common stock's financial health at 65/100. This is a data-driven snapshot of fundamentals, not investment advice.
Is MDLN stock overvalued?
Medline Inc. Class A common stock trades at a trailing P/E of 27.2 and our valuation score rates it 69/100 (higher = cheaper vs. its own history). See the Valuation History and Key Metrics sections for forward P/E, EV/EBITDA and PEG context.
When does Medline Inc. Class A common stock report earnings?
No confirmed earnings date is currently scheduled for MDLN. The Earnings section lists recent reports and updates as dates are announced.
What sector does Medline Inc. Class A common stock operate in?
Medline Inc. Class A common stock operates in the Healthcare sector, within the Surgical & Medical Instruments & Apparatus industry. The Related Stocks section lists sector peers for comparison.
What does Medline Inc. Class A common stock do?
Medline is the largest provider of medical-surgical products and supply chain solutions in the US.
About Medline Inc. Class A common stock (MDLN) Stock
Medline Inc. Class A common stock (MDLN) is a US-listed stock operating in the Healthcare sector, specifically the Surgical & Medical Instruments & Apparatus industry. As of the latest update, Medline Inc. Class A common stock is trading at $35.96, down 1.67% on the day with a market capitalization of $31.6 billion. The financial health score for MDLN is 65/100, which indicates good financial strength based on profitability, leverage, liquidity, and growth metrics. This page provides real-time pre-market pricing, earnings calendar, financial health analysis, and valuation metrics for MDLN stock.
MDLN Stock Analysis & Key Metrics
On PreMarketPrice, you can track Medline Inc. Class A common stock (MDLN) across multiple dimensions:
- Pre-market price & movement: Real-time MDLN stock price with percentage change, updated continuously during pre-market and regular trading hours.
- Valuation & P/E history: Historical P/E, P/S, and P/B ratios for MDLN with trend analysis and normalized valuation multiples.
- Financial statements: Revenue, net income, assets, liabilities, and equity for Medline Inc. Class A common stock across multiple reporting periods.
- Financial health score: A composite score of 65/100 based on Altman Z-Score, Piotroski F-Score, profitability, and leverage metrics for MDLN.
- Sector peers: Compare MDLN against 6 other healthcare stocks on key financial metrics.
Is MDLN a Good Stock to Buy?
This page provides data-driven analysis to help you evaluate Medline Inc. Class A common stock (MDLN) as an investment. The financial health score of 65/100 suggests good financial fundamentals. Valuation metrics show whether the stock is trading above or below its historical average.However, this is not financial advice — always do your own research before investing.
Data on this page is sourced from real-time market feeds, Polygon.io, and Finnhub.Medline Inc. Class A common stock (MDLN) trades on NYSE/NASDAQ. Pre-market trading occurs 4:00 AM – 9:30 AM ET. Regular market hours are 9:30 AM – 4:00 PM ET.